Literature DB >> 23219578

Electrophysiologically identified presynaptic mechanisms underlying amylinergic modulation of area postrema neuronal excitability in rat brain slices.

Takeshi Fukuda1, Yoshiyuki Hirai, Hitoshi Maezawa, Yoshimasa Kitagawa, Makoto Funahashi.   

Abstract

Amylin, which is co-secreted together with insulin by pancreatic beta cells, is considered to be an important peptide hormone involved in the control of feeding behavior and energy homeostasis. Although the area postrema has been implicated to be a primary target of amylin, there are no studies of the mechanisms by which amylin may alter the excitability of area postrema neurons. To investigate the mechanism for amylinergic modulation of neuronal excitability, we performed perforated patch-clamp recordings from area postrema neurons in rat brainstem slices. Amylin-induced changes in excitatory responses, such as increases in the frequency of mEPSCs (miniature excitatory postsynaptic currents) and changes in the amplitude distribution of mEPSCs, were found in cells not displaying the hyperpolarization-activated cation current (I(h)). Area postrema cells displaying I(h) did not respond to amylin application. Inhibitory responses to amylin were never encountered. Bath application of CNQX (AMPA type glutamate receptor antagonist) abolished the effects of amylin. Depolarization of cells during amylin application was sufficient at 1 μM to cause action potential discharge by responding cells. We conclude that amylin receptors are located mostly on presynaptic glutamatergic terminals connecting to the area postrema neurons not displaying I(h) and amylin concentrations can increase glutamate release enough to cause cell firing. Modulation of amylinergic activity may offer a novel target to influence food intake and obesity.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219578     DOI: 10.1016/j.brainres.2012.11.051

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.

Authors:  Wei Qiao Qiu
Journal:  Neuroscience       Date:  2017-05-19       Impact factor: 3.590

2.  Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake.

Authors:  Elizabeth G Mietlicki-Baase; Laura E Rupprecht; Diana R Olivos; Derek J Zimmer; Mark D Alter; R Christopher Pierce; Heath D Schmidt; Matthew R Hayes
Journal:  Neuropsychopharmacology       Date:  2013-03-08       Impact factor: 7.853

3.  5-HT neurons of the area postrema become c-Fos-activated after increases in plasma sodium levels and transmit interoceptive information to the nucleus accumbens.

Authors:  Rebecca L Miller; Arthur D Loewy
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-03-05       Impact factor: 3.619

Review 4.  Amylin at the interface between metabolic and neurodegenerative disorders.

Authors:  Thomas A Lutz; Urs Meyer
Journal:  Front Neurosci       Date:  2015-06-16       Impact factor: 4.677

5.  Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?

Authors:  Wei Qiao Qiu; Haihao Zhu
Journal:  Front Aging Neurosci       Date:  2014-07-29       Impact factor: 5.750

Review 6.  Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity.

Authors:  Christina Neuner Boyle; Thomas Alexander Lutz; Christelle Le Foll
Journal:  Mol Metab       Date:  2017-11-23       Impact factor: 7.422

Review 7.  Sensory Circumventricular Organs, Neuroendocrine Control, and Metabolic Regulation.

Authors:  Jin Kwon Jeong; Samantha A Dow; Colin N Young
Journal:  Metabolites       Date:  2021-07-29

Review 8.  Islet Amyloid Polypeptide: A Partner in Crime With Aβ in the Pathology of Alzheimer's Disease.

Authors:  Ana F Raimundo; Sofia Ferreira; Ivo C Martins; Regina Menezes
Journal:  Front Mol Neurosci       Date:  2020-03-20       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.